Outrun Therapeutics expands leadership team with appointment of Matthew Fyfe as Chief Scientific Officer

  • Brings extensive small molecule drug discovery, development, and clinical experience across multiple therapeutic areas
  • Will drive application of Outrun’s novel, proprietary X-E3L platform for protein stabiliser discovery to develop a pipeline of high-quality drug candidates targeting E3 ligases
  • Continues strong momentum following 2024 emergence from stealth with $10M seed financing

Dundee, Scotland – 13 January 2025 – Outrun Therapeutics (“Outrun”), the E3 ligase inhibitor and protein stabilisation specialist, today announces the appointment of Matthew Fyfe as its Chief Scientific Officer.

Read more…